Samsung Biologics and Afrinoia Sign Contract for Alzheimer's Treatment Contract Development

Samsung Biologics Plant 3 Internal Bioreactor Hall

[Asia Economy Reporter Choi Dae-yeol] Samsung Biologics announced on the 17th that it has signed a contract for contract development (CDO) with Taiwan's Afrinoia, which is developing an Alzheimer's treatment.

Under this contract, Samsung Biologics will be responsible for the overall development of Afrinoia's Alzheimer's treatment candidate, from cell line development to process development, clinical sample production, and clinical trial plan submission, producing global non-clinical and clinical materials. Afrinoia is a bio-venture developing diagnostic equipment and treatments for degenerative neurological diseases and is considered a leader in developing tau protein-targeting antibodies. Tau protein is a protein responsible for intracellular transport within neurons, known to accumulate in the human body and cause Alzheimer's and central nervous system diseases.

Samsung Biologics is pursuing an aggressive order acquisition strategy to expand its presence in the local market, currently negotiating additional contracts with more than 20 customers in the Greater China region. To date, it has carried out 48 CDO projects. The company plans to establish an integrated supply chain system for the entire biopharmaceutical production process and expand its CDO business area from the Americas, considered the largest market in the world, to the Greater China region.

Kim Tae-han, CEO of Samsung Biologics, said, "We hope this collaboration will accelerate the development of Alzheimer's treatment," adding, "We will successfully lead the product development of our clients with world-class development and production capabilities."

This content was produced with the assistance of AI translation services.